Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Dupixent continues to be a transformative medicine ... an additional share repurchase authorization. I'll conclude with a review of our 2025 financial guidance. We expect 2025 R&D spend to be ...

The EMA has started a review of Leo Pharma’s interleukin-13 ... a category that is currently dominated by Sanofi and Regeneron’s Dupixent. The EU regulator is reviewing tralokinumab for ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Dupixent becomes the first-ever targeted therapy ... The drug is also under review for this use in China, Japan, and other countries worldwide. Sanofi and Regeneron estimate that there are around ...

Dupixent has been a great drug ... Tolebrutinib will launch likely in SPMS this year, subject to regulatory review and approval, but that's our confidence and our aspiration.

Dupixent’s sales rose 16% year over year ... The FDA granted priority review to a supplemental new drug application (sNDA) seeking approval for Merck’s oral HIF-2α inhibitor, Welireg for ...